0000905718-21-000918.txt : 20210716
0000905718-21-000918.hdr.sgml : 20210716
20210716112753
ACCESSION NUMBER: 0000905718-21-000918
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
ITEM INFORMATION: Investment Company Act Section 3(c)
ITEM INFORMATION: Section 3(c)(1)
FILED AS OF DATE: 20210716
DATE AS OF CHANGE: 20210716
EFFECTIVENESS DATE: 20210716
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Life Sciences Innovation Fund II, L.P.
CENTRAL INDEX KEY: 0001870508
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-406537
FILM NUMBER: 211094622
BUSINESS ADDRESS:
STREET 1: 527 MADISON AVENUE, SUITE 2600
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 319-6625
MAIL ADDRESS:
STREET 1: 527 MADISON AVENUE, SUITE 2600
CITY: NEW YORK
STATE: NY
ZIP: 10022
D
1
primary_doc.xml
X0708
D
LIVE
0001870508
Life Sciences Innovation Fund II, L.P.
527 MADISON AVENUE, SUITE 2600
NEW YORK
NY
NEW YORK
10022
(212) 319-6625
DELAWARE
None
None
Limited Partnership
true
2021
-
Life Sciences Innovation GP LLC
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Director
General Partner
-
AWM Investment Company, Inc.
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Investment Manager
David
Sable
c/o Life Sciences Innovation GP LLC
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Director
Austin
Marxe
c/o Life Sciences Innovation GP LLC
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Director
David
Greenhouse
c/o Life Sciences Innovation GP LLC
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Director
Adam
Stettner
c/o Life Sciences Innovation GP LLC
527 Madison Avenue, Suite 2600
New York
NY
NEW YORK
10022
Executive Officer
Director
Pooled Investment Fund
Other Investment Fund
false
Decline to Disclose
- 06b
- 3C
- 3C.1
false
2021-05-17
true
true
false
0
Indefinite
10808755
Indefinite
false
38
0
true
0
true
The Issuer may from time to time elect to engage third party broker dealers. Any commissions and/or expenses paid to such broker dealers will be paid by the General Partner out of net profits.
0
true
The Investment Manager receives an asset based management fee.
false
Life Sciences Innovation Fund II, L.P.
/s/ Adam Stettner
Adam Stettner
Executive Officer
2021-07-16